Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
10.68
-0.15 (-1.43%)
Nov 10, 2026, 10:40 AM EST - Market open
Sagimet Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 165.9 | 35.02 | 75.84 | 75.14 | 0.16 | 56.73 |
Short-Term Investments | 74.23 | 78.1 | 75.41 | 19.76 | 32.19 | - |
Cash & Short-Term Investments | 240.13 | 113.12 | 151.25 | 94.9 | 32.35 | 56.73 |
Cash Growth | 91.48% | -25.21% | 59.38% | 193.39% | -42.98% | -17.42% |
Prepaid Expenses | 3.2 | 2.8 | 1.06 | 1.35 | 0.41 | 0.42 |
Other Current Assets | 0.66 | 0.48 | 0.46 | 0.4 | 0.03 | 1.51 |
Total Current Assets | 243.99 | 116.4 | 152.77 | 96.65 | 32.79 | 58.66 |
Property, Plant & Equipment | 1.95 | 0.08 | 0.08 | 0.07 | 0.21 | 0.34 |
Long-Term Investments | 17.44 | - | 7.41 | - | - | - |
Other Long-Term Assets | 0.06 | - | - | - | 0.03 | 0.03 |
Total Assets | 263.43 | 116.48 | 160.26 | 96.72 | 33.03 | 59.03 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.13 | 1.31 | 1.43 | 0.19 | 1.13 | 0.76 |
Accrued Expenses | 4.18 | 3.69 | 2.95 | 4.85 | 3.96 | 1.32 |
Current Portion of Leases | 0.08 | 0.08 | 0.08 | 0.07 | 0.13 | 0.12 |
Other Current Liabilities | 0.03 | 0.03 | 0.01 | 0.56 | 0.06 | 0.24 |
Total Current Liabilities | 5.42 | 5.1 | 4.45 | 5.65 | 5.28 | 2.44 |
Long-Term Leases | 1.86 | - | - | - | 0.08 | 0.22 |
Other Long-Term Liabilities | - | - | - | - | 0 | - |
Total Liabilities | 7.28 | 5.1 | 4.45 | 5.65 | 5.36 | 2.66 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 627.18 | 457.61 | 450.88 | 340.78 | 35 | 33.11 |
Retained Earnings | -370.95 | -346.35 | -295.31 | -249.74 | -221.87 | -191.37 |
Comprehensive Income & Other | -0.08 | 0.12 | 0.23 | 0.03 | -0.08 | - |
Total Common Equity | 256.16 | 111.38 | 155.81 | 91.07 | -186.95 | -158.26 |
Shareholders' Equity | 256.16 | 111.38 | 155.81 | 91.07 | 27.67 | 56.37 |
Total Liabilities & Equity | 263.43 | 116.48 | 160.26 | 96.72 | 33.03 | 59.03 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.94 | 0.08 | 0.08 | 0.07 | 0.21 | 0.35 |
Net Cash (Debt) | 255.62 | 113.05 | 158.58 | 94.83 | 32.13 | 56.38 |
Net Cash Growth | 88.91% | -28.71% | 67.22% | 195.11% | -43.01% | -17.68% |
Net Cash Per Share | 6.78 | 3.49 | 5.06 | 9.07 | 174.06 | 459.97 |
Filing Date Shares Outstanding | 62.16 | 32.59 | 32.2 | 31.91 | 22.9 | 0.12 |
Total Common Shares Outstanding | 61.78 | 32.52 | 32.2 | 22.9 | 0.19 | 0.12 |
Working Capital | 238.57 | 111.3 | 148.32 | 90.99 | 27.51 | 56.22 |
Book Value Per Share | 4.15 | 3.42 | 4.84 | 3.98 | -1010.08 | -1291.08 |
Tangible Book Value | 256.16 | 111.38 | 155.81 | 91.07 | -186.95 | -158.26 |
Tangible Book Value Per Share | 4.15 | 3.42 | 4.84 | 3.98 | -1010.08 | -1291.08 |